Reference : Newborn Screening for Sickle Cell Disease Using Tandem Mass Spectrometry
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/2300
Newborn Screening for Sickle Cell Disease Using Tandem Mass Spectrometry
English
Boemer, François mailto [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >]
Ketelslegers, Olivier [ > > ]
Minon, Jean-Marc [ > > ]
Bours, Vincent mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Génétique générale et humaine >]
Schoos, Roland mailto [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >]
2008
Clinical Chemistry
American Association for Clinical Chemistry
54
12
2036-2041
Yes (verified by ORBi)
International
0009-9147
1530-8561
Washington
DC
[en] Neonatal Screening ; Sickle Cell Disease ; Tandem Mass Spectrometry
[en] BACKGROUND: Neonatal screening programs for sickle cell disease are now widespread in North American and European countries. Most programs apply isoelectric focusing or HPLC to detect hemoglobin variants. Because tandem mass spectrometry (MS/MS) is being used for screening of inherited metabolic disorders and allows protein identification, it was worth testing for hemoglobinopathy screening. METHODS: We minimized sample preparation and analysis times by avoiding prior purification, derivatization, or separation. We developed a tryptic digestion methodology to screen for the main clinically important variants (HbS, HbC, and HbE) and beta-thalassemia. To ensure proper discrimination between homozygote and heterozygote variants, we selected 4 transitions with good signal intensities for each specific peptide and calculated variant/HbA ratios for each. Method validation included intra- and interseries variability, carryover, and limit of detection. We also performed a comparative study with isoelectric focusing results on 2082 specimens. RESULTS: Intraassay imprecision values (CVs) varied between 2.5% and 30.7%. Interassay CVs were between 6.3% and 23.6%. Carryover was <0.03%, and the limit of detection was fixed at 1% of HbS. According to the MS/MS settings (detection of HbS, HbC, HbE, and beta-globin production defects), the comparative study did not yield any discrepant results between the 2 techniques. CONCLUSIONS: MS/MS is a reliable method for hemoglobinopathy neonatal screening.
http://hdl.handle.net/2268/2300

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Art François ClinChem.pdfPublisher postprint142.76 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.